Thanks to the incredible dedication of the entire Ocular Therapeutix team, along with our outstanding investigators and study sites, we’re thrilled to announce that the SOL-1 Phase 3 trial for OTX-TKI will complete randomization this week, with more than 300 patients now randomized. This milestone marks a significant step forward in advancing treatments for retinal diseases, and we couldn’t be more excited about the potential impact for patients. Read more here: https://ow.ly/fiYh50UjeIJ. #OCUTX #wetAMD #NPDR #RetinalDiseases
关于我们
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX?. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Ocular Therapeutix has a commercially available drug product, DEXTENZA? (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis; the product is currently being marketed through a fully integrated specialty sales force. Ocular Therapeutix’s lead clinical program AXPAXLI? (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI, is currently being developed to treat wet AMD and diabetic retinopathy; other indications may also be pursued in due course. Other clinical programs include PAXTRAVA? (travoprost intracameral implant), also referenced as laboratory code OTX-TIC, for intracameral injection, for the treatment of elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for intracanalicular use, for the chronic treatment of dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for intracanalicular use, for the short-term treatment of the signs and symptoms of dry eye disease.
- 网站
-
https://www.ocutx.com
Ocular Therapeutix, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 51-200 人
- 总部
- Bedford，MA
- 类型
- 上市公司
- 创立
- 2006
- 领域
- ocular drug delivery、surgical sealants、sustained delivery、ophthalmic therapies、ophthalmology、optometry、retina、cataract、glaucoma、wet AMD、anti-vegf和drug delivery
地点
Ocular Therapeutix, Inc.员工
动态
-
Our team will be in Austin, TX, for the 13th Annual Vit Buckle Society Meeting, featuring cutting-edge discussions, innovative presentations, and networking opportunities with leading experts. We look forward to sharing more about our mission to redefine the retina experience. #RetinaRedefined #WetAMD #DiabeticRetinopathy
-
-
Wet age-related macular degeneration is a serious retinal condition that can lead to permanent vision loss. Ocular's Chief Medical Officer, Nadia Waheed, is excited about the next era of development for patients with retinal disease, and so are we. At Ocular Therapeutix, we're committed to redefining the experience of retinal disease across drug development, treatment, and outcomes. Learn more at https://lnkd.in/dPPzv8HQ. #RetinaRedefined #WetAMD
-
Join the Ocular Therapeutix team! #RetinaRedefined #NowHiring #PharmaceuticalDevelopment Click here to view the full job description: https://ow.ly/ecxT50VhAZc Click here for a full list of open positions: https://ow.ly/Ct5C50VhAXg
-
-
At Ocular Therapeutix, we're proud to celebrate the outstanding women who are pivotal in our mission to redefine the retina experience. Their dedication, innovation, and expertise drive our success and inspire us every day. Today, we're spotlighting Erica Kahn?for her invaluable contributions to our team. Join us in recognizing and celebrating the?extraordinary?women of Ocular Therapeutix this Women's History Month. #WomensHistoryMonth #RetinaRedefined
-
Wet age-related macular degeneration (AMD) is a burdensome retinal disease that occurs when blood vessels leak blood or fluid into a region of the retina called the macula, leading to impaired vision.1 Routine eye exams are crucial for the early detection of retinal diseases like AMD, which can help prevent vision loss.2 To learn more, visit ocutx.com/retina-focus/. #RetinaRedefined #WetAMD
-
-
We had an incredible experience at the Retina Consultants of America 2025 Meeting! Our team was thrilled to share how we are redefining the retina experience and engage with so many passionate retina specialists and the entire research staff. Thank you to everyone who attended our presentations and contributed to the insightful discussions. To learn more about our mission, visit https://ow.ly/k0ge50Vg0oO. #RetinaRedefined #WetAMD #DiabeticRetinopathy
-
-
It’s National Save Your Vision Month – a time to highlight the importance of protecting eye health. Retinal diseases like wet age-related macular degeneration can lead to vision loss or significant vision impairment.1 Regular visits to your eye care provider can help catch retinal disease early.2 At Ocular Therapeutix, we're working to redefine outcomes in the hope of preserving vision for the long term. To learn more about our mission, visit www.OCUTX.com. #NationalSaveYourVisionMonth #RetinaRedefined
-
-
This Employee Appreciation Day, we're grateful for our incredible team of employees who are helping to redefine the experience of retinal disease. Today and every day, we thank you for your expertise, collaboration, and dedication to improving patient outcomes! #RetinaRedefined #WetAMD #EmployeeAppreciationDay
-
-
This Women’s History Month, we're proud to spotlight one of our exceptional team members at Ocular Therapeutix, Jessica Grey. We agree with Jessica and know women like her are paving the way for progress. Our team is grateful for the impact she has had on our workplace as we aspire to redefine the retina experience. #WomensHistoryMonth #RetinaRedefined